{"id":"immune-checkpoint-inhibitors","safety":{"commonSideEffects":[{"rate":"20–30%","effect":"Fatigue"},{"rate":"15–25%","effect":"Diarrhea"},{"rate":"15–25%","effect":"Rash"},{"rate":"2–5%","effect":"Immune-related pneumonitis"},{"rate":"1–3%","effect":"Immune-related hepatitis"},{"rate":"1–3%","effect":"Immune-related colitis"},{"rate":"5–10%","effect":"Hypothyroidism"}]},"_chembl":{"chemblId":"CHEMBL2108699","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These drugs work by inhibiting checkpoint proteins (such as PD-1, PD-L1, or CTLA-4) that cancer cells use to evade immune detection. By removing these 'brakes' on the immune system, checkpoint inhibitors restore T cell activation and proliferation, enabling enhanced anti-tumor immunity. This mechanism has proven effective across multiple cancer types.","oneSentence":"Immune checkpoint inhibitors block inhibitory signals on T cells, allowing the immune system to recognize and attack cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:48:15.294Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Various solid tumors and hematologic malignancies (specific indications depend on the particular checkpoint inhibitor agent)"}]},"trialDetails":[{"nctId":"NCT04317105","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-17","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":54},{"nctId":"NCT07495579","phase":"PHASE2","title":"Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2026-04","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":146},{"nctId":"NCT07495215","phase":"PHASE1, PHASE2","title":"A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection","status":"RECRUITING","sponsor":"Yinghua Xu","startDate":"2025-09-11","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":20},{"nctId":"NCT07466238","phase":"NA","title":"HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2026-03-15","conditions":"Biliary Tract Cancer (BTC)","enrollment":40},{"nctId":"NCT04615988","phase":"","title":"Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2021-06-09","conditions":"Thyroid, PD-1, Cancer","enrollment":17},{"nctId":"NCT06694454","phase":"PHASE1, PHASE2","title":"Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma","enrollment":60},{"nctId":"NCT06346197","phase":"PHASE3","title":"Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2025-12-08","conditions":"Gastric Cancer, MSI-H, Metastatic Cancer","enrollment":132},{"nctId":"NCT06994377","phase":"","title":"Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy","status":"RECRUITING","sponsor":"European Institute of Oncology","startDate":"2025-06-25","conditions":"Metastatic Breast Cancer","enrollment":1000},{"nctId":"NCT06745908","phase":"PHASE3","title":"ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-10-01","conditions":"NSCLC Stage IV","enrollment":460},{"nctId":"NCT05427487","phase":"PHASE1","title":"Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours","status":"RECRUITING","sponsor":"ImmVirx Pty Ltd","startDate":"2023-02-17","conditions":"Colorectal Cancer, Gastric Cancer, Ovarian Cancer","enrollment":70},{"nctId":"NCT02484404","phase":"PHASE1, PHASE2","title":"Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-06-29","conditions":"Colorectal Neoplasms, Breast Neoplasms","enrollment":268},{"nctId":"NCT07281924","phase":"PHASE1, PHASE2","title":"Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-04","conditions":"Metastatic Melanoma, Liver Metastases","enrollment":15},{"nctId":"NCT06314334","phase":"PHASE2","title":"Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-04","conditions":"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type","enrollment":210},{"nctId":"NCT04476563","phase":"","title":"Checkpoint Inhibitor-induced Liver Injury","status":"RECRUITING","sponsor":"University of Nottingham","startDate":"2020-10-13","conditions":"Immune-Mediated Hepatitis","enrollment":160},{"nctId":"NCT07131007","phase":"","title":"Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-09-15","conditions":"Malignant Neoplasm, Organ Damage","enrollment":2000},{"nctId":"NCT07059494","phase":"PHASE4","title":"Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-06","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT07487805","phase":"PHASE2","title":"Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC)","status":"NOT_YET_RECRUITING","sponsor":"University of Florida","startDate":"2026-07","conditions":"Solid Tumor, Adult","enrollment":80},{"nctId":"NCT07478679","phase":"PHASE1","title":"Radiation to Treat Joint Damage Caused by Cancer Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-08-26","conditions":"Arthritis, Arthropathy","enrollment":20},{"nctId":"NCT07487519","phase":"PHASE2","title":"Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-04-25","conditions":"Breast Cancer (Triple Negative Breast Cancer (TNBC))","enrollment":180},{"nctId":"NCT06738160","phase":"PHASE2","title":"The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-15","conditions":"NSCLC, Stereotactic Body Radiation Therapy (SBRT), Immunotherapy","enrollment":27},{"nctId":"NCT04038619","phase":"PHASE1","title":"Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-01","conditions":"Colitis, Diarrhea, Malignant Genitourinary System Neoplasm","enrollment":40},{"nctId":"NCT07486492","phase":"EARLY_PHASE1","title":"Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2026-03-31","conditions":"Colorectal Cancer Metastatic, Fecal Microbiota Transplantation","enrollment":10},{"nctId":"NCT04637594","phase":"PHASE3","title":"Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2022-05-27","conditions":"Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma","enrollment":3},{"nctId":"NCT07484022","phase":"PHASE1","title":"Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Generate Biomedicines","startDate":"2026-03","conditions":"Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma","enrollment":37},{"nctId":"NCT05411133","phase":"PHASE1","title":"Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients","status":"COMPLETED","sponsor":"Arbele Pty Ltd","startDate":"2022-05-30","conditions":"Gastrointestinal Cancer, Cholangiocarcinoma, Liver Cancer","enrollment":33},{"nctId":"NCT04338269","phase":"PHASE3","title":"A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2020-07-28","conditions":"Carcinoma, Renal Cell","enrollment":522},{"nctId":"NCT07479485","phase":"PHASE1, PHASE2","title":"MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)","status":"NOT_YET_RECRUITING","sponsor":"Lepu Biopharma Co., Ltd.","startDate":"2026-04","conditions":"Hepatocellular Carcinoma","enrollment":160},{"nctId":"NCT05941741","phase":"PHASE3","title":"IC Plus Low-dose Radiation Plus Cadonilimab in LANPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-01-10","conditions":"Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy","enrollment":380},{"nctId":"NCT07475403","phase":"PHASE2","title":"Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Second Hospital","startDate":"2026-03-16","conditions":"Bladder Cancer, Liquid Biopsy, Immunotherapy","enrollment":53},{"nctId":"NCT05101070","phase":"PHASE1, PHASE2","title":"S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Shionogi","startDate":"2022-05-30","conditions":"Solid Tumors","enrollment":282},{"nctId":"NCT02973789","phase":"PHASE3","title":"Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)","status":"COMPLETED","sponsor":"NovoCure GmbH","startDate":"2016-12","conditions":"Nonsmall Cell Lung Cancer, NSCLC","enrollment":291},{"nctId":"NCT07396467","phase":"","title":"Clinical Outcomes and Immunotherapy in Lung Cancer With Pulmonary Fibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-11-01","conditions":"Lung Cancer (Diagnosis), Pulmonary Fibrosis, Interstitial Lung Diseases","enrollment":200},{"nctId":"NCT07403136","phase":"PHASE2","title":"Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-02-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":52},{"nctId":"NCT04943848","phase":"PHASE1","title":"rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG","status":"RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2022-01-10","conditions":"Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant","enrollment":36},{"nctId":"NCT03547973","phase":"PHASE2","title":"Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2018-08-13","conditions":"Metastatic Urothelial Cancer","enrollment":827},{"nctId":"NCT07339254","phase":"","title":"Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study","status":"RECRUITING","sponsor":"University of Southern California","startDate":"2026-03-12","conditions":"Lung Non-Small Cell Carcinoma","enrollment":40},{"nctId":"NCT07320586","phase":"PHASE2","title":"Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Shandong Tumor Hospital","startDate":"2021-03-01","conditions":"Gastric Cancer, Second-line Therapy","enrollment":40},{"nctId":"NCT07192315","phase":"NA","title":"Predicting Reactions and Effects of Drugs Immunotherapy and Complications Through Oncosafety (PREDICTO Clinical Study)","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2026-04","conditions":"Solid Tumor Malignancies, Solid Cancers","enrollment":160},{"nctId":"NCT07322341","phase":"PHASE2","title":"SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"University of Washington","startDate":"2026-06-01","conditions":"Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma","enrollment":32},{"nctId":"NCT05364086","phase":"","title":"An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Rochester NCORP Research Base","startDate":"2022-04-26","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm","enrollment":2100},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT04590963","phase":"PHASE3","title":"Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-10-02","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":370},{"nctId":"NCT07466225","phase":"","title":"HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2026-03-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":150},{"nctId":"NCT06989112","phase":"PHASE3","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-27","conditions":"Endometrial Cancer","enrollment":600},{"nctId":"NCT07468630","phase":"PHASE2","title":"Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-04-10","conditions":"Colon Adenocarcinoma","enrollment":106},{"nctId":"NCT07359040","phase":"","title":"Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-07-01","conditions":"Non-Small Cell Lung Cancer, Neoadjuvant Therapy, PD-1 Inhibitors","enrollment":80},{"nctId":"NCT05338775","phase":"PHASE1","title":"A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-05-25","conditions":"Relapsed/ Refractory Multiple Myeloma","enrollment":74},{"nctId":"NCT06349642","phase":"","title":"Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-04-24","conditions":"Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma","enrollment":324},{"nctId":"NCT06218303","phase":"PHASE1","title":"Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ","status":"RECRUITING","sponsor":"Finn, Olivera, PhD","startDate":"2024-02-07","conditions":"Ductal Carcinoma in Situ","enrollment":50},{"nctId":"NCT03819296","phase":"PHASE1","title":"Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-21","conditions":"Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8","enrollment":800},{"nctId":"NCT07381634","phase":"PHASE2","title":"The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2026-03-20","conditions":"Hepatocellular Carcinoma (HCC), IrAE","enrollment":134},{"nctId":"NCT03313804","phase":"PHASE2","title":"Priming Immunotherapy in Advanced Disease With Radiation","status":"COMPLETED","sponsor":"John L. Villano, MD, PhD","startDate":"2017-10-26","conditions":"Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck","enrollment":76},{"nctId":"NCT07069712","phase":"PHASE2","title":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-17","conditions":"Gastroesophageal Adenocarcinoma","enrollment":100},{"nctId":"NCT05378334","phase":"NA","title":"Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients","status":"RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2022-06-15","conditions":"Non-small Cell Lung Cancer","enrollment":82},{"nctId":"NCT04697576","phase":"PHASE1","title":"Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma","status":"RECRUITING","sponsor":"Carlo Contreras","startDate":"2021-10-20","conditions":"Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8","enrollment":36},{"nctId":"NCT05824481","phase":"PHASE2","title":"Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-05-08","conditions":"Endometrial Cancer, Endometrial Adenocarcinoma","enrollment":32},{"nctId":"NCT05824468","phase":"PHASE2","title":"Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-05-10","conditions":"Cervical Cancer, Cervical Carcinoma","enrollment":30},{"nctId":"NCT06821503","phase":"PHASE1, PHASE2","title":"Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-11","conditions":"Advanced Pancreatic Cancer","enrollment":72},{"nctId":"NCT06819735","phase":"PHASE1, PHASE2","title":"Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Domain Therapeutics Australia Pty Ltd","startDate":"2025-06-25","conditions":"Advanced Solid Tumors","enrollment":125},{"nctId":"NCT07228442","phase":"PHASE2","title":"L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Philogen S.p.A.","startDate":"2026-02","conditions":"Locally Advanced Cutaneous Squamous Cell Carcinoma","enrollment":92},{"nctId":"NCT07216495","phase":"NA","title":"Pilot Study of Aerobic Exercise During Immune Checkpoint Inhibitor Therapy in Early-Stage TNBC","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-02-23","conditions":"Aerobic Exercise, Early Stage Triple Negative Breast Cancer","enrollment":33},{"nctId":"NCT07457099","phase":"","title":"Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2026-04-01","conditions":"Locally Advanced Oral Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma","enrollment":85},{"nctId":"NCT06951646","phase":"PHASE2","title":"ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)","status":"RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2026-03-10","conditions":"Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)","enrollment":70},{"nctId":"NCT07453394","phase":"PHASE1, PHASE2","title":"QLS5132 Combination Therapy in Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-04","conditions":"Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC), Endometrial Cancer","enrollment":626},{"nctId":"NCT07455734","phase":"PHASE1, PHASE2","title":"Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"BioNTech SE","startDate":"2026-03","conditions":"Advanced Solid Tumor Cancer","enrollment":533},{"nctId":"NCT07453342","phase":"","title":"Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-01-01","conditions":"Immune-Related Adverse Events","enrollment":500},{"nctId":"NCT07079631","phase":"PHASE1, PHASE2","title":"A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-07-18","conditions":"Metastatic Colorectal Cancer","enrollment":482},{"nctId":"NCT06647680","phase":"PHASE2","title":"Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）","status":"RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2025-06-01","conditions":"Rectal Cancer Patients","enrollment":35},{"nctId":"NCT06096779","phase":"PHASE2","title":"A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2024-07-15","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT07456358","phase":"NA","title":"Autoimmune Neurological Diseases and Those Secondary to Immunotherapy: Study of Immunological Mechanisms and Research Into Targets of Immune Attack","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-03-01","conditions":"Neurological Diseases, Auto Immune Disease","enrollment":160},{"nctId":"NCT06472245","phase":"PHASE3","title":"Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor","status":"RECRUITING","sponsor":"OSE Immunotherapeutics","startDate":"2024-12-03","conditions":"Patients With Non-Small Cell Lung Cancer","enrollment":363},{"nctId":"NCT06239727","phase":"PHASE3","title":"Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-03-01","conditions":"Nasopharyngeal Carcinoma","enrollment":593},{"nctId":"NCT06857279","phase":"PHASE2","title":"A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2025-04-22","conditions":"Carcinoma of Head and/or Neck","enrollment":167},{"nctId":"NCT07452003","phase":"NA","title":"An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-01-03","conditions":"Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT06807593","phase":"PHASE2","title":"Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-02-24","conditions":"Cancer","enrollment":10},{"nctId":"NCT07205731","phase":"PHASE2","title":"Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2025-10-07","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":95},{"nctId":"NCT04880382","phase":"PHASE2","title":"Integrative Analysis of Tumor Microenvironment and Optimization of Immunotherapy Duration in NSCL Cancer Patients","status":"TERMINATED","sponsor":"Institut Bergonié","startDate":"2021-08-27","conditions":"Non Small Cell Lung Cancer","enrollment":8},{"nctId":"NCT06545955","phase":"PHASE3","title":"A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Ferring Pharmaceuticals","startDate":"2024-10-01","conditions":"Non-muscle Invasive Bladder Cancer With Carcinoma in Situ","enrollment":250},{"nctId":"NCT07354100","phase":"PHASE1, PHASE2","title":"Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-12-15","conditions":"Cancer","enrollment":55},{"nctId":"NCT06632327","phase":"PHASE3","title":"Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2024-12-11","conditions":"Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":1100},{"nctId":"NCT07231445","phase":"PHASE1","title":"Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2026-03","conditions":"Small Cell Lung Cancer","enrollment":100},{"nctId":"NCT05467670","phase":"PHASE2","title":"Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexander B Olawaiye, MD","startDate":"2023-03-30","conditions":"Ovarian Cancer","enrollment":16},{"nctId":"NCT06037811","phase":"PHASE2","title":"Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis","status":"RECRUITING","sponsor":"Tom Appleton","startDate":"2024-04-15","conditions":"Inflammatory Arthritis, Immune-related Adverse Event","enrollment":30},{"nctId":"NCT07276880","phase":"PHASE2","title":"Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-03","conditions":"Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-Negative Breast Carcinoma","enrollment":32},{"nctId":"NCT07436390","phase":"NA","title":"IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma","status":"COMPLETED","sponsor":"Institute of Oncology Ljubljana","startDate":"2024-03-31","conditions":"Metastatic Melanoma, Malignant Melanoma, Skin Cancer","enrollment":132},{"nctId":"NCT06502691","phase":"PHASE1, PHASE2","title":"[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-02-26","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma","enrollment":22},{"nctId":"NCT07411105","phase":"","title":"Cognition in Older Adults With Cancer Receiving Systemic Anti-Cancer Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Our Lady's Hospice and Care Services","startDate":"2024-05-21","conditions":"Cancer, Older Adults (65 Years and Older), Cognition","enrollment":30},{"nctId":"NCT06103864","phase":"PHASE3","title":"A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-23","conditions":"Breast Cancer","enrollment":625},{"nctId":"NCT06772623","phase":"PHASE1, PHASE2","title":"Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-03-06","conditions":"Non Small Cell Lung Carcinoma","enrollment":252},{"nctId":"NCT03535545","phase":"PHASE1","title":"Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2018-08-01","conditions":"Pulmonary Fibrosis, Lung Cancer","enrollment":100},{"nctId":"NCT04969887","phase":"PHASE2","title":"Combination Immunotherapy in Rare Cancers Under InvesTigation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Olivia Newton-John Cancer Research Institute","startDate":"2021-08-03","conditions":"Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm","enrollment":240},{"nctId":"NCT07110103","phase":"PHASE2","title":"Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-10-31","conditions":"SCLC, SCLC, Extensive Stage","enrollment":20},{"nctId":"NCT04990726","phase":"","title":"Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-12-05","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8","enrollment":126},{"nctId":"NCT07213830","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies","status":"RECRUITING","sponsor":"Ipsen","startDate":"2026-02-06","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":102},{"nctId":"NCT04290546","phase":"PHASE1","title":"CIML NK Cell in Head & Neck Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-07-20","conditions":"Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":11},{"nctId":"NCT04093323","phase":"PHASE2","title":"Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2024-11-13","conditions":"HLA-A2 Positive Cells Present, Refractory Melanoma","enrollment":1},{"nctId":"NCT07434518","phase":"","title":"A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-01-27","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":500},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT07428252","phase":"NA","title":"Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2022-03-01","conditions":"Metastatic Malignant Melanoma","enrollment":150},{"nctId":"NCT07432984","phase":"PHASE2","title":"Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Se-Hoon Lee","startDate":"2026-04-30","conditions":"Non Small Cell Lung Cancer","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":33713,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Camrelizumab, Sintilimab, Nivolumab, Pembrolizumab, Toripalimab","Nivolumab","Pembrolizumab","Atezolizumab","Durvalumab"],"phase":"marketed","status":"active","brandName":"Immune Checkpoint Inhibitors","genericName":"Immune Checkpoint Inhibitors","companyName":"The Central Hospital of Lishui City","companyId":"the-central-hospital-of-lishui-city","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Immune checkpoint inhibitors block inhibitory signals on T cells, allowing the immune system to recognize and attack cancer cells. Used for Various solid tumors and hematologic malignancies (specific indications depend on the particular checkpoint inhibitor agent).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}